Memantine Centrafarm (Memantine)

Memantine blocks the NMDA receptor’s ion channel in a non‑competitive manner, reducing excessive calcium entry caused by glutamate over‑activation and thereby limiting excitotoxic neuronal damage that contributes to dementia.

The dosage of memantine is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and tolerability. Patients should follow the prescriber’s instructions exactly.

The safety of memantine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

Enquiries can be submitted on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Memantine belongs to the NMDA receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil. It is typically used in moderate to severe stages, often in combination with an acetylcholinesterase inhibitor for complementary mechanisms.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture and direct sunlight to maintain product stability.

Memantine Centrafarm is taken orally, usually with or without food, as directed by the prescriber. Swallow the tablet whole with water; do not crush or chew unless specifically instructed.

Serious risks include seizures, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and emergence of suicidal thoughts. Patients should seek immediate medical attention if any of these occur.

Memantine is contraindicated in patients with known hypersensitivity to the drug, those taking other NMDA antagonists, and individuals with uncontrolled severe renal or hepatic impairment unless closely monitored.